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Abstract
Background:  Decisions on treatment are guided, not only by the potential for benefit, but also
by the nature and severity of adverse drug reactions. However, some researchers have found
numerous deficiencies in trial reports of adverse effects. We sought to confirm these findings by
evaluating trials of drug therapy published in seven eminent medical journals in 1997.
Methods:  Literature review to determine whether the definition, recording and reporting of
adverse drug reactions in clinical trials were in accordance with published recommendations on
structured reporting.
Results:  Of the 185 trials reviewed, 25 (14%) made no mention of adverse drug reactions. Data
in a further 60 (32%) could not be fully evaluated, either because numbers were not given for each
treatment arm (31 trials), or because a generic statement was made without full details (29 trials).
When adverse drug reactions such as clinical events or patient symptoms were mentioned in the
reports, details on how they had been recorded were given in only 14/95 (15%) and 18/104 (17%)
trials respectively. Of the 86 trials that mentioned severity of adverse drug reactions, only 42 (49%)
stated how severity had been defined. The median amount of space used for safety data in the
Results and Discussion sections was 5.8%.
Conclusions:  Trial reports often failed to provide details on how adverse drug reactions were
defined or recorded. The absence of such methodological information makes comparative
evaluation of adverse reaction rates potentially unreliable. Authors and journals should adopt
recommendations on the structured reporting of adverse effects.
Background
Although drug safety information is of vital importance,
evidence is now emerging that adverse drug reactions
(ADRs) are often inadequately reported in randomised,
controlled trials [1,2]. Lack of consistency in ADR report-
ing has important implications – it makes systematic re-
views of ADR data extremely difficult and also hinders
comparisons of ADR rates between trials. For example,
the authors of a recent systematic review of beta-block-
ers in myocardial infarction were able to draw conclu-
sions on the efficacy of treatment, but not safety, because
"different definitions and reporting made comparisons
between trials problematic" [3].
Two aspects of reporting are particularly important
when comparing rates of ADRs in different trials [4].
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Firstly, adverse event recording in trials may frequently
include unfavourable outcomes that arise from disease
progression or concomitant co-morbidity, and are unre-
lated to drug treatment. Trial reports of adverse events
need to make it clear which ones are thought to be ADRs.
Secondly, different methods of recording ADRs can lead
to significantly different results. For example, Olsen et
al's study of hypertensive patients showed that rates of
ADRs varied depending on whether spontaneous report-
ing, general enquiry, or specific questioning had been
used in detecting ADRs (rates of 16%, 24%, and 62% re-
spectively) [5]. ADR data can be reliably interpreted only
when there is information on how they were recorded.
Although the original CONSORT statement made no
mention of adverse effects, the recent revised statement
recommends only that "all important adverse events or
side effects [are reported] in each intervention group"
[6]. More detailed recommendations on the structured
reporting of ADRs were made by the SORT committee in
1994 [7]. Trials should:
• define what constituted adverse events and how they
were monitored by the intervention group;
• present sufficient simple (unadjusted) summary data
on primary outcome measures and important adverse ef-
fects for the reader to reproduce the result.
We carried out our study to determine if the reporting of
ADRs in a wide selection of randomised controlled trials
was in accordance with these recommendations.
Methods
Selection of trials
We used a sample of randomised controlled trials that
had been published in seven general medical journals:
The New England Journal of Medicine, The Journal of
the American Medical Association, The Lancet, The Brit-
ish Medical Journal, Annals of Internal Medicine, Ar-
chives of Internal Medicine, and The American Journal
of Medicine. We selected these journals because they are
highly ranked in the Science Citation Index and provide
a relatively broad coverage of general medical topics. The
Cochrane Controlled Trials Register was used to identify
all the randomised controlled trials from these journals
in the year 1997 [8]. As our primary objective was to eval-
uate the reporting of drug ADRs, we reviewed only those
trials in which at least one treatment arm involved a
pharmacological intervention. We excluded papers in
which the main bulk of the data had been published else-
where, e.g. post hoc or subgroup analyses of trials, or pa-
pers that stated that adverse effects data were or would
be available in a separate publication. A complete list of
the trials evaluated is available from the authors.
Two reviewers assessed all trials independently, using a
checklist, and any discrepancies were resolved through
discussion.
Evaluation
The review checklist was based largely on the recommen-
dations of SORT; our main criteria were that:
1. ADRs should be clearly and appropriately defined;
2. there should be sufficient detail on how the reported
ADRs were elicited and recorded (including definitions
of severity) so that the reader can fully interpret the re-
sult or reproduce the study if necessary;
3. frequencies of adverse effects should be reported in a
simple, coherent manner.
We also measured the amount of space (area in cm2) in
the Results and Discussion sections that was devoted to
ADR reports.
Details are given below on the specific criteria used in
evaluating ADR reports.
Clear and appropriate use of ADR definitions
Adverse drug reactions have been defined as those
"where the causal relation between the product and an
adverse event is at least a reasonable possibility", while
the less specific (but widely used) term "adverse events"
should be reserved for describing untoward occurrences
that are not necessarily causally related to the treatment
[9,10]. The terms should not be used interchangeably.
The use of terminology was considered appropriate if tri-
als reported drug safety with terms such as "adverse drug
reactions", "adverse or side effects" or "drug toxicity", or
if they explicitly stated which adverse events were possi-
bly related to drug treatment. Reports of adverse out-
comes without clarification of their relation to drug
treatment were considered to be inadequate.
Sufficient detail on methods used in monitoring of ADRs 
for the reader to interpret or reproduce the result
When ADRs were reported, we asked whether it was pos-
sible for readers to tell which specific methods had been
used in the detection or recording of ADRs. We evaluated
the following areas of ADR monitoring – symptoms re-
ported by patients, events diagnosed clinically by physi-
cians, and abnormalities detected using investigative
tests.
Patients' symptoms
We asked whether the trial report explained how the
rates of symptomatic ADRs had been determined duringBMC Clinical Pharmacology 2001, 1:3 http://www.biomedcentral.com/1472-6904/1/3
the course of the study; for example, by spontaneous re-
porting, patient diary or checklist questionnaire.
ADRs presenting as clinical events diagnosed by physicians
We asked whether the reported ADRs had been detected
with specific, targeted clinical assessments or purely
from spontaneous reports as they arose. In particular, we
looked for detail of systematic surveillance measures e.g.
investigators were asked to take blood pressure readings
at 15 minute intervals to look for hypotension; rates of
gastrointestinal haemorrhages were monitored through
routine checking of hospital records.
ADRs detected through the use of diagnostic tests
We asked whether the trial specified which diagnostic
techniques had been used in detecting the reported
ADRs; for example, was deep venous thrombosis diag-
nosed by ultrasonography or by contrast venography? In
cases in which laboratory tests were used, we asked
whether the laboratory values or criteria for diagnosing
an abnormality were stated; for example, was hypokalae-
mia diagnosed at serum potassium concentrations below
3.0 mmol/l?
Severity
We looked for details on the severity of the reported
ADRs and, if present, whether the measures of severity
were made according to recognized scales (such as the
National Cancer Institute Toxicity Grades[11]), or other-
wise defined e.g. "major bleeds were those that were fatal
or required transfusion".
Nature of ADR reporting
Numerical data
When ADRs were reported, we asked whether simple
summary (unadjusted) data were always given for each
treatment arm; were there instances in which data were
given as a lumped total (e.g. headache noted in 5% of all
patients in the trial), or for only one treatment arm?
We also looked at the prevalence of statements that could
not be fully interpreted owing to lack of detail on the fre-
quency and/or type of adverse effect; e.g. "The pattern
and profile of adverse effects were similar" or "The treat-
ments were well tolerated". Such generic statements, in
the absence of any supporting information, are not help-
ful in evaluating the frequency of ADRs [2].
Space for reporting adverse events
We measured the area (cm2) used for reporting ADRs
(text, figures and tables) in the Results and Discussion
sections of the published paper, and expressed it as a
percentage of the total area of the Results and Discussion
sections.
Results
Of the 185 eligible trials, 25 (13.5%) made no mention of
adverse effects in any part of the paper and were there-
fore not analysed further.
Definition of ADRs
We found 48 trials out of 160 (30%) in which it was not
clear which (if any) of the reported adverse events were
considered to be drug-related. For instance, in a study of
captopril for heart failure, cough (a well-recognised ADR
of captopril) was listed together with other untoward in-
cidents, such as myocardial infarction, in a table of ad-
verse events [12]. Systematic reviewers and members of
the public who are unfamiliar with pharmacology may
end up erroneously believing that myocardial infarction
is a harmful drug-related effect of captopril, when in fact,
myocardial infarction is a recognised complication of the
underlying illness.
Monitoring of ADRs
Details of the methods used in ascertaining the rate of
ADRs were more likely to be given when an investigative
test was required for diagnosis of the ADR (Table 1). In
contrast, many trials merely said that patients were rou-
tinely assessed for the presence of ADRs such as clinical
events, or new symptoms. It was usually unclear whether
this involved targeted clinical assessments for particular
ADRs, or if it was left to the patients to report any unto-
ward events.
Grade of severity
Of the 86 trials that commented on the severity of the re-
ported ADRs, more than half (44 trials, 51%) did not give
details on how severity was defined or which, if any, rec-
ognized severity grading system was used.
Reporting
Numerical data
Of the 160 trials that mentioned ADRs, analysis of the
full dataset was not possible in 60 (38%) trials. Nineteen
gave figures on ADRs for one treatment arm only (with-
out details of figures for the other arms) and 12 provided
lumped totals without specifying the numbers that oc-
curred in individual arms. Information on ADRs in a fur-
ther 29 trials could not be fully analysed because it was
based on generic statements without adequate definition
or supporting numerical data.
A summary of the findings is shown in Figure 1.
Proportion of space for reporting adverse effects in the Results and 
Discussion section
The median proportion of space devoted to ADR report-
ing in the Results and Discussion section was 5.8%, and
the mean was 8.2% (interquartile range of 1.7–12%).BMC Clinical Pharmacology 2001, 1:3 http://www.biomedcentral.com/1472-6904/1/3
Discussion
"Readers should not have to infer what was probably
done, they should be told explicitly" wrote Altman in
support of the recommendations on better reporting of
randomised controlled trials [13]. Disappointingly, in
this series of trials it was often not possible to tell what
had been done to define or detect the reported ADRs.
Most authors were content either to say that adverse ef-
fects were assessed routinely (leaving the reader to infer
the exact methods), or gave no information at all, ignor-
Figure 1
Reporting of adverse drug reactions – flow chart summary of results.
Table 1: Availability of information on the methods used in recording ADRs, categorized according to type of ADRs reported by the 
trial.
Types of ADRs No. of trials Specific details given on how Did not specify methods
reporting rate of reported ADRs were used in determining the
recorded rate of reported ADRs
Detected by 68 37 (55%) 31 (45%)
investigative tests
Clinical events 95 14 (15%) 81 (85%)
Patient symptoms 104 18 (17%) 86 (83%)BMC Clinical Pharmacology 2001, 1:3 http://www.biomedcentral.com/1472-6904/1/3
ing the SORT recommendation that sufficient detail
should be given for readers to reproduce the results.
This leaves us in a quandary when we try to interpret
rates of ADRs. Perceived differences in drug safety pro-
files may result simply from the use of different methods,
rather than reflecting any genuine disparity. For exam-
ple, trials that found relatively high rates of ADRs may
have done so because patients' diaries, rather than spon-
taneous reporting, were used in monitoring ADRs [1]. A
similar lack of information on the criteria (or grading
system) used in gauging the severity of ADRs makes it
difficult to assess their clinical impact. There will be dif-
ferences in the reported rate, and clinical significance, of
an ADR such as hypokalaemia if it was diagnosed at plas-
ma potassium concentrations below 3.0 mmol/l in one
trial, and at levels below 3.5 mmol/l in another. As these
methodological details are seldom fully described in trial
reports, any comparative evaluation of ADR rates be-
tween trials should be viewed as being potentially unre-
liable.
Although deviations from a precise definition of the term
"ADR" may seem to be a minor issue, closer analysis re-
veals how misleading conclusions may result from the
inappropriate use of terminology. A systematic review of
postoperative analgesia found piroxicam to have a signif-
icantly better safety profile than placebo [14]. However,
on closer examination, we found that symptoms such as
fever and headache were recorded as adverse effects in
the piroxicam trials. Piroxicam (a non-steroidal anti-in-
flammatory drug) is an effective treatment for fevers and
headaches, and it is therefore no surprise that placebo
turned out to have a greater rate of "adverse effects" and
was considered less safe. In order to avoid potential con-
fusion, authors should provide sufficient information in
adverse event reports for readers to be aware of which
events were defined as ADRs, and which were considered
to be adverse clinical events unrelated to therapy.
We recognise that trials may be insufficiently powered
for detection of rare adverse effects and cannot be ex-
pected to detect and report all adverse effects associated
with a drug. We also do not mean to imply that trials pro-
viding long lists of ADRs are better than those that report
few. However, our primary concern is that adverse ef-
fects data, when available, should be reported in a con-
sistent manner. Specific steps for monitoring ADRs have
already been laid down under the International Confer-
ence on Harmonisation – Good Clinical Practice guide-
lines for clinical trials, and it is regrettable that much of
the information collected is not reported in a useful for-
mat [9].
Authors may argue that space constraints in journals
prevent them from reporting ADRs in more detail. How-
ever, we found that many papers used only a small pro-
portion of space for reporting safety data – 68% of the
reviewed trials devoted less than 10% of the total area in
the Results and Discussion section to describing adverse
effects. Greater clarity in the reporting of ADRs could be
achieved if authors were prepared to reduce the empha-
sis on efficacy and devote a greater proportion of space to
safety. In addition, journals that maintain a web pres-
ence could be asked to provide dedicated areas for the re-
porting of adverse effects data.
Systematic reviews summarising the effects of health
care have recently been accused of bias, because they em-
phasise efficacy rather than safety [15]. However, the dis-
parate nature of ADR reporting does not facilitate
systematic analysis, and it is therefore no surprise that
systematic reviews are unable to provide a balanced
viewpoint. Patients and their physicians will not be able
to make accurate judgements on the benefit:harm ratio
unless safety reporting receives equal attention. Wide-
spread adoption of the SORT recommendations on the
reporting of adverse effects would substantially improve
the quality of information without adding greatly to the
burden of work for authors.
In summary, we believe that the absence of methodolog-
ical detail, and lack of coherency in reporting the rates of
ADRs creates significant problems for those trying to in-
terpret the data. Authors need to:
• specify the methods used in detecting ADRs (incidental
reporting, routine recording, or active seeking)
• define ADRs, and the scale of severity used
• report the frequencies of ADRs for each treatment arm
Valuable evidence on ADRs will continue to be misinter-
preted or lost unless these measures are adopted by au-
thors and journal editors.
Conclusions
Trial reports often failed to provide details on how ad-
verse drug reactions were defined or recorded. The ab-
sence of such methodological details makes comparative
evaluation of adverse effects rates between trials poten-
tially unreliable, and hinders systematic review or meta-
analysis of such data. The quality of the information
would be significantly improved if authors and journals
adopted recommendations on structured reporting of
adverse effects.BMC Clinical Pharmacology 2001, 1:3 http://www.biomedcentral.com/1472-6904/1/3
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